Tapewire

Nasdaq · USD

PCRX

Pacira BioSciences, Inc.

Export transactions ↓
Tapewire entity
4928
SEC CIK
0001396814
Parsed reports
428

Last 12 months

Inside the activity.

0 purchase rows · 17 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202502
Dec 202502
Jan 202601
Feb 202602
Mar 202602
Apr 202604
May 202600
Jun 202602
Jul 202600
Aug 202601
Sep 202600
Oct 202601

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 08, 2026 Filed Oct 9, 2026 23:07 UTC
RIKER LAURENSenior Vice President, Finance
Exercise / conversionStock Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $32.35 $0.00
Disclosure

SEC source: 0001628280-26-065566 · wk-form4_1791587267.xml · derivative · entry 3

RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2026-12-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.

F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years.

F1 · derivative.underlying_shares: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.

Read SEC document
October 08, 2026 Filed Oct 9, 2026 23:07 UTC
RIKER LAURENSenior Vice President, Finance
SaleCommon Stock 6,000 $36.32 $217,920.00
Disclosure

SEC source: 0001628280-26-065566 · wk-form4_1791587267.xml · nonDerivative · entry 2

RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,284.242

F1 · shares: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.

Read SEC document
October 08, 2026 Filed Oct 9, 2026 23:07 UTC
RIKER LAURENSenior Vice President, Finance
Exercise / conversionCommon Stock 6,000 $32.35 $194,100.00
Disclosure

SEC source: 0001628280-26-065566 · wk-form4_1791587267.xml · nonDerivative · entry 1

RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,284.242

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.

Read SEC document
August 17, 2026 Filed Aug 18, 2026 21:21 UTC
SLONIN JONATHANChief Medical Officer
SaleCommon Stock 3,040 $23.23 $70,619.20
Disclosure

SEC source: 0001628280-26-057759 · wk-form4_1787088074.xml · nonDerivative · entry 1

SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 216,383.646

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025.

F2 · balance_after: Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan in June 2026.

Read SEC document
June 11, 2026 Filed Jun 13, 2026 01:07 UTC
RIKER LAURENSenior Vice President, Finance
SaleCommon Stock 6,115 $23.50 $143,702.50
Disclosure

SEC source: 0001628280-26-043009 · wk-form4_1781312864.xml · nonDerivative · entry 1

RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,284.242

F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:07 UTC GrantStock Option (Right to Buy) · Derivative 10,891 $0.00 Strike: $23.42 $0.00
Disclosure

SEC source: 0001628280-26-043010 · wk-form4_1781312871.xml · derivative · entry 2

Hirawat Samit · CIK 0001781290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,891

Underlying: Common Stock · 10,891 shares

Expires 2036-06-10

F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:07 UTC GrantCommon Stock 6,405 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-043010 · wk-form4_1781312871.xml · nonDerivative · entry 1

Hirawat Samit · CIK 0001781290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,405

F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:06 UTC GrantStock Option (Right to Buy) · Derivative 10,891 $0.00 Strike: $23.42 $0.00
Disclosure

SEC source: 0001628280-26-043003 · wk-form4_1781312816.xml · derivative · entry 2

Froimson Mark · CIK 0001709050 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,891

Underlying: Common Stock · 10,891 shares

Expires 2036-06-10

F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:06 UTC GrantCommon Stock 6,405 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-043003 · wk-form4_1781312816.xml · nonDerivative · entry 1

Froimson Mark · CIK 0001709050 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,541

F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC GrantStock Option (Right to Buy) · Derivative 32,675 $0.00 Strike: $23.42 $0.00
Disclosure

SEC source: 0001628280-26-043007 · wk-form4_1781312848.xml · derivative · entry 1

WIGGANS THOMAS G · CIK 0001208907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,675

Underlying: Common Stock · 32,675 shares

Expires 2036-06-10

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:06 UTC
Brege LauraDirector
GrantStock Option (Right to Buy) · Derivative 10,891 $0.00 Strike: $23.42 $0.00
Disclosure

SEC source: 0001628280-26-043002 · wk-form4_1781312808.xml · derivative · entry 2

Brege Laura · CIK 0001365619 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,891

Underlying: Common Stock · 10,891 shares

Expires 2036-06-10

F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:06 UTC
Brege LauraDirector
GrantCommon Stock 6,405 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-043002 · wk-form4_1781312808.xml · nonDerivative · entry 1

Brege Laura · CIK 0001365619 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,120

F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC GrantStock Option (Right to Buy) · Derivative 10,891 $0.00 Strike: $23.42 $0.00
Disclosure

SEC source: 0001628280-26-043008 · wk-form4_1781312856.xml · derivative · entry 2

CHRISTIE CHRISTOPHER · CIK 0001787688 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,891

Underlying: Common Stock · 10,891 shares

Expires 2036-06-10

F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC GrantCommon Stock 6,405 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-043008 · wk-form4_1781312856.xml · nonDerivative · entry 1

CHRISTIE CHRISTOPHER · CIK 0001787688 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,059

F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC GrantStock Option (Right to Buy) · Derivative 10,891 $0.00 Strike: $23.42 $0.00
Disclosure

SEC source: 0001628280-26-043006 · wk-form4_1781312840.xml · derivative · entry 2

Young Alethia · CIK 0001918147 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,891

Underlying: Common Stock · 10,891 shares

Expires 2036-06-10

F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC GrantCommon Stock 6,405 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-043006 · wk-form4_1781312840.xml · nonDerivative · entry 1

Young Alethia · CIK 0001918147 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,798

F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC GrantStock Option (Right to Buy) · Derivative 10,891 $0.00 Strike: $23.42 $0.00
Disclosure

SEC source: 0001628280-26-043005 · wk-form4_1781312832.xml · derivative · entry 2

YANG MICHAEL J. · CIK 0001702283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,891

Underlying: Common Stock · 10,891 shares

Expires 2036-06-10

F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC GrantCommon Stock 6,405 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-043005 · wk-form4_1781312832.xml · nonDerivative · entry 1

YANG MICHAEL J. · CIK 0001702283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,798

F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC GrantStock Option (Right to Buy) · Derivative 10,891 $0.00 Strike: $23.42 $0.00
Disclosure

SEC source: 0001628280-26-043004 · wk-form4_1781312824.xml · derivative · entry 2

BIGAL MARCELO · CIK 0001996637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,891

Underlying: Common Stock · 10,891 shares

Expires 2036-06-10

F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC GrantCommon Stock 6,405 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-043004 · wk-form4_1781312824.xml · nonDerivative · entry 1

BIGAL MARCELO · CIK 0001996637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,798

F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 04, 2026 Filed Jun 5, 2026 21:57 UTC
WILLIAMS KRISTENChief Administrative Officer
SaleCommon Stock 10,259 $22.27 $228,467.93
Disclosure

SEC source: 0001628280-26-041330 · wk-form4_1780696617.xml · nonDerivative · entry 2

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 167,062

F2 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.

Read SEC document
June 03, 2026 Filed Jun 5, 2026 21:57 UTC
SLONIN JONATHANChief Medical Officer
Tax withholdingCommon Stock 4,728 $22.32 $105,528.96
Disclosure

SEC source: 0001628280-26-041331 · wk-form4_1780696625.xml · nonDerivative · entry 1

SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 218,912.175

F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document
June 03, 2026 Filed Jun 5, 2026 21:57 UTC
WILLIAMS KRISTENChief Administrative Officer
Tax withholdingCommon Stock 8,528 $22.32 $190,344.96
Disclosure

SEC source: 0001628280-26-041330 · wk-form4_1780696617.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,321

F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document
June 03, 2026 Filed Jun 5, 2026 21:57 UTC
RIKER LAURENSenior Vice President, Finance
Tax withholdingCommon Stock 3,187 $22.32 $71,133.84
Disclosure

SEC source: 0001628280-26-041332 · wk-form4_1780696632.xml · nonDerivative · entry 1

RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,399.242

F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document
April 23, 2026 Filed Apr 25, 2026 00:41 UTC
Cross ShawnChief Financial Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 12,941 $0.00 Strike: $16.45 $0.00
Disclosure

SEC source: 0001628280-26-027287 · wk-form4_1777077683.xml · derivative · entry 3

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 12,941 shares

Expires 2034-11-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

F1 · derivative.underlying_shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

Read SEC document
April 23, 2026 Filed Apr 25, 2026 00:41 UTC
Cross ShawnChief Financial Officer
SaleCommon Stock 12,941 $25.16 $325,595.56
Disclosure

SEC source: 0001628280-26-027287 · wk-form4_1777077683.xml · nonDerivative · entry 2

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,341

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
April 23, 2026 Filed Apr 25, 2026 00:41 UTC
Cross ShawnChief Financial Officer
Exercise / conversionCommon Stock 12,941 $16.45 $212,879.45
Disclosure

SEC source: 0001628280-26-027287 · wk-form4_1777077683.xml · nonDerivative · entry 1

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,282

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

Read SEC document
April 22, 2026 Filed Apr 23, 2026 00:03 UTC
Cross ShawnChief Financial Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 1,500 $0.00 Strike: $16.45 $0.00
Disclosure

SEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · derivative · entry 9

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 162,941

Underlying: Common Stock · 1,500 shares

Expires 2034-11-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

F1 · derivative.underlying_shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

Read SEC document
April 22, 2026 Filed Apr 23, 2026 00:03 UTC
Cross ShawnChief Financial Officer
SaleCommon Stock 1,500 $25.01 $37,515.00
Disclosure

SEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 6

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,341

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive.

Read SEC document
April 22, 2026 Filed Apr 23, 2026 00:03 UTC
Cross ShawnChief Financial Officer
Exercise / conversionCommon Stock 1,500 $16.45 $24,675.00
Disclosure

SEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 5

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,841

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

Read SEC document
April 21, 2026 Filed Apr 23, 2026 00:03 UTC
Cross ShawnChief Financial Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 2,845 $0.00 Strike: $16.45 $0.00
Disclosure

SEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · derivative · entry 8

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 164,441

Underlying: Common Stock · 2,845 shares

Expires 2034-11-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

F1 · derivative.underlying_shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

Read SEC document
April 21, 2026 Filed Apr 23, 2026 00:03 UTC
Cross ShawnChief Financial Officer
SaleCommon Stock 2,845 $25.01 $71,153.45
Disclosure

SEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 4

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,341

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive.

Read SEC document
April 21, 2026 Filed Apr 23, 2026 00:03 UTC
Cross ShawnChief Financial Officer
Exercise / conversionCommon Stock 2,845 $16.45 $46,800.25
Disclosure

SEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 3

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,186

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

Read SEC document
April 20, 2026 Filed Apr 23, 2026 00:03 UTC
Cross ShawnChief Financial Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 7,714 $0.00 Strike: $16.45 $0.00
Disclosure

SEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · derivative · entry 7

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 167,286

Underlying: Common Stock · 7,714 shares

Expires 2034-11-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

F1 · derivative.underlying_shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

Read SEC document
April 20, 2026 Filed Apr 23, 2026 00:03 UTC
Cross ShawnChief Financial Officer
SaleCommon Stock 7,714 $25.14 $193,929.96
Disclosure

SEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 2

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,341

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3.

Read SEC document
April 20, 2026 Filed Apr 23, 2026 00:03 UTC
Cross ShawnChief Financial Officer
Exercise / conversionCommon Stock 7,714 $16.45 $126,895.30
Disclosure

SEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 1

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

Read SEC document
March 17, 2026 Filed Mar 19, 2026 21:43 UTC
SLONIN JONATHANChief Medical Officer
SaleCommon Stock 3,261 $22.82 $74,416.02
Disclosure

SEC source: 0001628280-26-019891 · wk-form4_1773956586.xml · nonDerivative · entry 1

SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 223,640.175

F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025.

Read SEC document
March 17, 2026 Filed Mar 19, 2026 17:43 UTC SaleCommon Stock 500 $21.81 $10,905.00
Disclosure

SEC source: 0001628280-26-019890 · wk-form4_1773956578.xml · nonDerivative · entry 1

Froimson Mark · CIK 0001709050 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,136

Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:01 UTC
SLONIN JONATHANChief Medical Officer
GrantCommon Stock 54,546 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-008075 · wk-form4_1771016513.xml · nonDerivative · entry 1

SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,901.175

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:02 UTC
Cross ShawnChief Financial Officer
GrantCommon Stock 49,091 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-008080 · wk-form4_1771016540.xml · nonDerivative · entry 1

Cross Shawn · CIK 0001734779 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,341

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:02 UTC
WILLIAMS KRISTENChief Administrative Officer
GrantCommon Stock 54,546 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-008078 · wk-form4_1771016534.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,849

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:02 UTC
Teehan BrendanChief Commercial Officer
GrantCommon Stock 51,714 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-008077 · wk-form4_1771016527.xml · nonDerivative · entry 1

Teehan Brendan · CIK 0001891900 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,934.268

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:02 UTC
RIKER LAURENSenior Vice President, Finance
GrantCommon Stock 19,273 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-008076 · wk-form4_1771016519.xml · nonDerivative · entry 1

RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,586.242

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:01 UTC
Lee Frank D.Director · Chief Executive Officer
GrantCommon Stock 261,818 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-008074 · wk-form4_1771016507.xml · nonDerivative · entry 1

Lee Frank D. · CIK 0001814686 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 660,830.841

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
February 02, 2026 Filed Feb 3, 2026 23:24 UTC
WILLIAMS KRISTENChief Administrative Officer
SaleCommon Stock 13,137 $20.53 $269,702.61
Disclosure

SEC source: 0001628280-26-005157 · wk-form4_1770161039.xml · nonDerivative · entry 2

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131,303

F2 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
February 02, 2026 Filed Feb 3, 2026 23:24 UTC
RIKER LAURENSenior Vice President, Finance
SaleCommon Stock 4,000 $20.81 $83,240.00
Disclosure

SEC source: 0001628280-26-005158 · wk-form4_1770161045.xml · nonDerivative · entry 2

RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,313.242

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.35 to $21.28, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3.

Read SEC document
January 30, 2026 Filed Feb 3, 2026 23:23 UTC
SLONIN JONATHANChief Medical Officer
Tax withholdingCommon Stock 6,168 $20.54 $126,690.72
Disclosure

SEC source: 0001628280-26-005155 · wk-form4_1770161031.xml · nonDerivative · entry 1

SLONIN JONATHAN · CIK 0001875723 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,355.175

F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document
January 30, 2026 Filed Feb 3, 2026 23:24 UTC
WILLIAMS KRISTENChief Administrative Officer
Tax withholdingCommon Stock 17,134 $20.54 $351,932.36
Disclosure

SEC source: 0001628280-26-005157 · wk-form4_1770161039.xml · nonDerivative · entry 1

WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,440

F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document
January 30, 2026 Filed Feb 3, 2026 23:24 UTC
RIKER LAURENSenior Vice President, Finance
Tax withholdingCommon Stock 2,751 $20.54 $56,505.54
Disclosure

SEC source: 0001628280-26-005158 · wk-form4_1770161045.xml · nonDerivative · entry 1

RIKER LAUREN · CIK 0001545439 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,313.242

F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document
January 30, 2026 Filed Feb 3, 2026 23:23 UTC
Teehan BrendanChief Commercial Officer
Tax withholdingCommon Stock 5,182 $20.54 $106,438.28
Disclosure

SEC source: 0001628280-26-005154 · wk-form4_1770161023.xml · nonDerivative · entry 1

Teehan Brendan · CIK 0001891900 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,220.268

F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.